CROs, trial sites and preclinical research companies at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
57 CROs, trial sites and preclinical research companies are at ObesityWeek 2026 — 36 presentations on the program and 40 with a booth in the exhibit hall. Most represented: Gubra (4 on the program), Parexel (2 on the program), WuXi AppTec (2 on the program). 43 of them have their own page in this guide. As of Nov 12, 2026.
Topic
Top represented
Showing 1–13 of 57 organizations
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Gubra Hørsholm, Denmark | |
Preclinical CRO and peptide drug-discovery company offering obesity and metabolic disease models and studies. | Poster Sat Nov 14 7:30pm–8:30pm Modeling Sarcopenic Obesity for Treatment of Healthy Weight Loss Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Superior Efficacy and Translatability of CagriSema Vs Cagrilintide and Semaglutide in DIO Rats Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Dexamethasone Induces Robust Skeletal Muscle Atrophy and Functional Decline in Mice Metabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Orforglipron Induces Weight Loss and Activates Appetite-Suppressing Brain Regions in a HGLP-1R Model Interventional and clinical studies |
Parexel Durham, NC | |
Global contract research organization that designs and runs clinical trials for drug developers, with regulatory and consulting services. | Booth Exhibiting at Booth 115 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sun Nov 15 2:30pm–3:30pm Operational Excellence in Early-Phase Obesity Trials: Protocol, Retention, and Timeline Insights Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Healthy Obese is Not a Traditional Healthy Volunteer: Considerations in Early Obesity Drug Trials Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Vision-Threatening Ocular Safety of GLP-1 Receptor Agonists: A Propensity-Matched Study Obesity pharmacotherapy and drug developmentInterventional and clinical studies |
WuXi AppTec Shanghai, China | |
Contract research, development and manufacturing company whose preclinical services include mouse models of obesity and metabolic liver disease for drug testing. | Booth Exhibiting at Booth 123 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sat Nov 14 7:30pm–8:30pm SiRNA‑Mediated ALK7 Knockdown Improves Metabolic Response to Tirzepatide and Preserves Lean Mass Metabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Novel High‑Fat Diets Rapidly Produce Next‑Generation Mouse Models of Metabolic Dysfunction-Associated Steatohepatitis Metabolism and integrative physiology |
MB Monroe Biomedical Research Monroe, NC | |
Clinical trial site network that owns its research sites, including the Louisville Metabolic and Atherosclerosis Research Center in Kentucky. | Poster Sun Nov 15 2:30pm–3:30pm Impact of SC VK2735 on Obesity Severity and Cardiometabolic Parameters in the VENTURE Study Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Efficacy, Safety, and Tolerability of CRB-913 in the Phase 1b CANYON-1 Study Interventional and clinical studiesObesity pharmacotherapy and drug development Talk Mon Nov 16 5:45pm–6:00pm |
Taconic Biosciences Rensselaer, NY | |
Provides genetically engineered, humanized and diet-induced obese rodent models and related services for preclinical research. | Poster Sat Nov 14 7:30pm–8:30pm Cagrilintide Reduces Body Weight and Prevents Adiposity Gain in Diet-Induced Obese Rats Metabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Humanized GLP-1R Mice Enable Translational Evaluation of Orforglipron With Reduced Energy Intake and Improved Glucose Tolerance Metabolism and integrative physiology Poster Mon Nov 16 2:30pm–3:30pm Obesity Alters Anti–PD-1 Tumor Response and Metabolic Signatures in a Syngeneic Colon Mouse Model Chronic disease and obesity complications |
LR Lifedoc Research | |
Clinical research group studying adiposity and cardiometabolic risk in underserved adults. | Poster Sat Nov 14 7:30pm–8:30pm Association of Coverage Type With Adiposity and Cardiometabolic Risk in Underserved African American and Hispanic Adolescents Chronic disease and obesity complicationsMetabolism and integrative physiology Talk Mon Nov 16 12:00pm–1:00pm Association of Coverage Type With Adiposity and Cardiometabolic Risk in Underserved African American and Hispanic Adolescents Pediatric and adolescent obesity |
Preclinical contract research company specializing in metabolic and cardiometabolic disease models. | Poster Sat Nov 14 7:30pm–8:30pm Semaglutide, Tirzepatide and Retatrutide Promote Metabolic Benefits in Obese Hamsters Metabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Individual Metabolic Phenotyping Uncovers the Acute Effects of Semaglutide in Hamsters Metabolism and integrative physiology |
The Jackson Laboratory Bar Harbor, ME | |
Independent nonprofit biomedical research institution that also supplies mouse models and preclinical study services, including obese and humanized mouse models. | Poster Sun Nov 15 2:30pm–3:30pm Generation and Characterization of an Immunodeficient Obese Mouse Model Recapitulating Metabolic Dysfunction Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm DIO Tg32 (hFcRn) Mice: A Translational PK Platform for Anti-Obesity Fc and Antibody Therapeutics Interventional and clinical studies |
Preclinical research company offering human adipose tissue models, efficacy screening and a biobank of adipose tissue and cells. | Booth Exhibiting at Booth 329 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sat Nov 14 7:30pm–8:30pm A Functional 3D Model of Human Adipose Lobule Combining Adipocyte Progenitors and Mature Adipocytes Chronic disease and obesity complicationsObesity pharmacotherapy and drug development |
US clinical research company with 20+ owned sites running obesity and metabolic trials from first-in-human to Phase 3, plus metabolic assessments. | Booth Exhibiting at Booth 203 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sun Nov 15 2:30pm–3:30pm Treatment Discontinuation and Weight Regain Bias Treatment Effect Estimates in Obesity Trials Obesity pharmacotherapy and drug developmentInterventional and clinical studies |
Syneos Health Morrisville, NC | |
Biopharmaceutical services company combining clinical research with commercialization support, informed by patient, physician and real-world insights. | Booth Exhibiting at Booth 300, Suite 5b Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Mon Nov 16 2:30pm–3:30pm Uncovering Barriers to Therapy Adoption by Patient GLP-1 Use Status: A Cross-Sectional Analysis Using an AI-Enabled Patient Priority Tool Clinical obesity care and professional practice |
Clinical research company linking consented patients and their health records to registries, trial recruitment and decentralized studies, including a cardiometabolic disease registry. | Booth Exhibiting at Booth 846 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Mon Nov 16 2:30pm–3:30pm |
Antaros Medical Mölndal, Sweden | |
Imaging contract research organization that runs MRI and PET studies for drug development, including body-composition and organ-fat measures. | Poster Sun Nov 15 2:30pm–3:30pm Adipose Tissue Fat Fraction and the Associations With Age, a UK Biobank Analysis Interventional and clinical studies |
Find buyers from CROs, trial sites and preclinical research companies
Tell us what you sell and we’ll find the people at these CROs, trial sites and preclinical research companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ObesityWeek 2026 by
Organization type
Topic
- Obesity pharmacotherapy and drug development 251
- Clinical obesity care and professional practice 196
- Interventional and clinical studies 231
- Metabolism and integrative physiology 217
- Nutrition, diet and food 164
- Pediatric and adolescent obesity 117
- Population health and epidemiology 156
- Chronic disease and obesity complications 224
- Neuroscience of appetite and eating 97
- Bariatric surgery and devices 58
- Policy and public health 102
Exhibit hall
Everyone
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction